ARTV_OUT_1 [2025-04-01 07:44:04 -0400] 2140 Bytes | 570 tokens | Cum: 570 tkns (7.12% of 8k)
==========================================================================

You're the expert here today. So, I pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Artiva Biotherapeutics (ARTV) hit my radar screen, up to 3.45 from a prev close of 3 Do you think its got more juice or is it lacking potential? It's 7:44:03 AM on Tue Apr 01, 2025 -0400 and I have to decide: buy or sell!

Here's the first list of news for Artiva Biotherapeutics:

C1 - Mar-31-25 04:05PM - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
C2 - Mar-24-25 04:05PM - Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
C3 - Feb-20-25 04:05PM - Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
C4 - Jan-29-25 04:05PM - Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
C5 - Nov-12-24 04:05PM - Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
C6 - Nov-11-24 04:05PM - Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
C7 - Oct-22-24 04:05PM - Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
C8 - Sep-10-24 04:05PM - Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Artiva Biotherapeutics (ARTV)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ARTV_OUT_3 [2025-04-01 07:44:10 -0400] 1099 Bytes | 307 tokens | Cum: 879 tkns (10.99% of 8k)
==========================================================================

Showing C2 (chunk 1 of 6): C2:
**Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights**
Date: Mar-24-25 04:05PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/24/3048295/0/en/Artiva-Biotherapeutics-Reports-Full-Year-2024-Financial-Results-and-Recent-Business-Highlights.html

March 24, 2025 16:05 ET| Source:Artiva Biotherapeutics, Inc.Artiva Biotherapeutics, Inc.San Diego, California

Initial data for AlloNK®from autoimmune program expected H1 2025

Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025

Strengthened key leadership with cell therapy and autoimmune expertise across organization

Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ARTV_OUT_5 [2025-04-01 07:44:11 -0400] 938 Bytes | 269 tokens | Cum: 1272 tkns (15.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T20:05:00Z - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Art...
A2 - 2025-03-31T20:13:47Z - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference...
A3 - 2025-03-31T20:16:23Z - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference | Tai...
A4 - 2025-03-29T12:06:42Z - Equities Analysts Set Expectations for ARTV Q1 Earnings...
A5 - 2025-03-28T10:32:23Z - Brokers Offer Predictions for ARTV FY2025 Earnings...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ARTV_OUT_7 [2025-04-01 07:44:14 -0400] 1098 Bytes | 304 tokens | Cum: 1578 tkns (19.73% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Artiva Biotherapeutics (NASDAQ:ARTV)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/03/g44570745/artiva-biotherapeutics-to-participate-in-the-24th-annual-needham-virtual-healthcare-conferenceSAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. ARTV, a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT.

Members of the Artiva management team will also be available to participate in investor meetings with investors

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ARTV_OUT_9 [2025-04-01 07:44:15 -0400] 398 Bytes | 105 tokens | Cum: 1755 tkns (21.94% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-28T18:00:00Z - NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ARTV_OUT_11 [2025-04-01 07:44:17 -0400] 829 Bytes | 211 tokens | Cum: 1968 tkns (24.60% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/28/3034967/0/en/NK-Cell-Therapy-Market-on-Track-for-Exponential-Growth-Amid-Rising-Pipeline-Developments-DelveInsight.htmlThe NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ARTV_OUT_13 [2025-04-01 07:44:18 -0400] 805 Bytes | 206 tokens | Cum: 2240 tkns (28.00% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing els...

S2 - 2025-03-24 8-K Item2.02

Results of Oper and Fin Cond.

On March 24, 2025, Artiva Biotherapeutics, Inc. (Artiva) issued a press release announcing its financial results for the year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ARTV_OUT_15 [2025-04-01 07:44:21 -0400] 1098 Bytes | 221 tokens | Cum: 2463 tkns (30.79% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
It em 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance that involve risks, uncertainties and assumptions, such as statements regarding our intentions, plans, objectives and expectations for our business. Our actual results and the timing of selected events could differ materially from those described in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ARTV_OUT_17 [2025-04-01 07:44:29 -0400] 5264 Bytes | 1536 tokens | Cum: 4093 tkns (51.16% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+----------------------+
| Volume: 64,656 | Perf Month: -27.71% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 98.75K | Perf Quarter: -71.51% | Short Float: 7.12% | ROE: - |
+--------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.66 | Index: RUT | Short Ratio: 8.65 | ROI: -33.14% |
+--------------------+-----------------------+------------------------+----------------------+
| RSI (14): 33.53 | Market Cap: 73.09M | Short Interest: 0.85M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.64 | Shs Outstand: 24.29M | Beta: - | EPS Surprise: 9.73% |
+--------------------+-----------------------+------------------------+----------------------+
| SMA20: -35.08% | Shs Float: 11.99M | Sales Q/Q: -100.00% | P/E: - |
+--------------------+-----------------------+------------------------+----------------------+
| SMA50: -35.89% | Inst Own: 63.16% | Sales past 5Y: 125.25% | Earnings: Mar 24 AMC |
+--------------------+-----------------------+------------------------+----------------------+
| SMA200: -68.82% | Insider Own: 50.78% | Employees: 89 | |
+--------------------+-----------------------+------------------------+----------------------+
| Perf Week: -23.27% | Insider Trans: 0.00% | Debt/Eq: 0.08 | |
+--------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Aslan Fred (President and CEO) on 2025-03-05
- Common Stock: 200000 shares at $0 (D)

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Bush Jennifer (COO, CLO, Secy, Compliance Off) on 2025-02-26
- Common Stock: 86650 shares at $0 (D)

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Krishnamohan Neha (Chief Financial Officer) on 2025-02-26
- Common Stock: 60000 shares at $0 (D)

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Horan Christopher (Chief Tech Operations Officer) on 2025-02-26
- Common Stock: 60000 shares at $0 (D)

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Graef Thorsten (Chief Medical Officer) on 2025-02-26
- Common Stock: 60000 shares at $0 (D)

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Raymon Heather (SVP, Research and Development) on 2025-02-26
- Common Stock: 33350 shares at $0 (D)

No transactions recorded.

Inside Trans: Artiva Biotherapeutics, Inc. (ARTV) by Baker Daniel G. (Unknown Title) on 2025-01-28
- Director Stock Option (Right to Buy): 27500 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 251000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -65373000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3
Average Volume: 141338.62
30-Day High: 6.25
30-Day Low: 3

[Detailed Financials: TTM 2024]
- Total Assets: $209,581,000.0
- Total Liabilities: $22,940,000.0
- Total Equity: $186,641,000.0
- Current Assets: $188,631,000.0
- Current Liabilities: $12,253,000.0

[Income Statement: TTM 2024]
- Revenue: $251,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.81

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-13,269,000.0

[Detailed Financials: FY 2024]
- Total Assets: $209,581,000.0
- Total Liabilities: $22,940,000.0
- Total Equity: $186,641,000.0
- Current Assets: $188,631,000.0
- Current Liabilities: $12,253,000.0

[Income Statement: FY 2024]
- Revenue: $251,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.81

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-13,269,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ARTV_OUT_19 [2025-04-01 07:44:31 -0400] 676 Bytes | 167 tokens | Cum: 4506 tkns (56.33% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ARTV_IN_21 [2025-04-01 07:44:31 -0400] 126 Bytes | 29 tokens | Cum: 4563 tkns (57.04% of 8k)
==========================================================================

====================================
[2025-04-01 07:44:31] # Analysis Completed
Elapsed Time: 28.90 seconds